Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
Accurate detection and reliable assessment of therapeutic responses in bone metastases are imperative for guiding treatment decisions, preserving quality of life, and ultimately enhancing overall survival. Nuclear imaging has historically played a pivotal role in this realm, offering a diverse range...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1320574/full |
| _version_ | 1827381587837190144 |
|---|---|
| author | Eric Ouvrard Ashjan Kaseb Ashjan Kaseb Nathan Poterszman Clémence Porot Francois Somme Alessio Imperiale Alessio Imperiale |
| author_facet | Eric Ouvrard Ashjan Kaseb Ashjan Kaseb Nathan Poterszman Clémence Porot Francois Somme Alessio Imperiale Alessio Imperiale |
| author_sort | Eric Ouvrard |
| collection | DOAJ |
| description | Accurate detection and reliable assessment of therapeutic responses in bone metastases are imperative for guiding treatment decisions, preserving quality of life, and ultimately enhancing overall survival. Nuclear imaging has historically played a pivotal role in this realm, offering a diverse range of radiotracers and imaging modalities. While the conventional bone scan using 99mTc marked bisphosphonates has remained widely utilized, its diagnostic performance is hindered by certain limitations. Positron emission tomography, particularly when coupled with computed tomography, provides improved spatial resolution and diagnostic performance with various pathology-specific radiotracers. This review aims to evaluate the performance of different nuclear imaging modalities in clinical practice for detecting and monitoring the therapeutic responses in bone metastases of diverse origins, addressing their limitations and implications for image interpretation. |
| first_indexed | 2024-03-08T13:58:28Z |
| format | Article |
| id | doaj.art-d24bd11b15db4314a60763ba9c8b1030 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-08T13:58:28Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-d24bd11b15db4314a60763ba9c8b10302024-01-15T09:51:37ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-01-011010.3389/fmed.2023.13205741320574Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?Eric Ouvrard0Ashjan Kaseb1Ashjan Kaseb2Nathan Poterszman3Clémence Porot4Francois Somme5Alessio Imperiale6Alessio Imperiale7Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, FranceNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, FranceRadiology, College of Medicine, University of Jeddah, Jeddah, Saudi ArabiaNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, FranceRadiopharmacy, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, FranceNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, FranceNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, FranceIPHC, UMR 7178, CNRS/Unistra, Strasbourg, FranceAccurate detection and reliable assessment of therapeutic responses in bone metastases are imperative for guiding treatment decisions, preserving quality of life, and ultimately enhancing overall survival. Nuclear imaging has historically played a pivotal role in this realm, offering a diverse range of radiotracers and imaging modalities. While the conventional bone scan using 99mTc marked bisphosphonates has remained widely utilized, its diagnostic performance is hindered by certain limitations. Positron emission tomography, particularly when coupled with computed tomography, provides improved spatial resolution and diagnostic performance with various pathology-specific radiotracers. This review aims to evaluate the performance of different nuclear imaging modalities in clinical practice for detecting and monitoring the therapeutic responses in bone metastases of diverse origins, addressing their limitations and implications for image interpretation.https://www.frontiersin.org/articles/10.3389/fmed.2023.1320574/fullbone metastasesbone scan99mTc18 F-FDG18 F-fluorocholine68Ga-DOTA |
| spellingShingle | Eric Ouvrard Ashjan Kaseb Ashjan Kaseb Nathan Poterszman Clémence Porot Francois Somme Alessio Imperiale Alessio Imperiale Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine? Frontiers in Medicine bone metastases bone scan 99mTc 18 F-FDG 18 F-fluorocholine 68Ga-DOTA |
| title | Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine? |
| title_full | Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine? |
| title_fullStr | Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine? |
| title_full_unstemmed | Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine? |
| title_short | Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine? |
| title_sort | nuclear medicine imaging for bone metastases assessment what else besides bone scintigraphy in the era of personalized medicine |
| topic | bone metastases bone scan 99mTc 18 F-FDG 18 F-fluorocholine 68Ga-DOTA |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1320574/full |
| work_keys_str_mv | AT ericouvrard nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine AT ashjankaseb nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine AT ashjankaseb nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine AT nathanpoterszman nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine AT clemenceporot nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine AT francoissomme nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine AT alessioimperiale nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine AT alessioimperiale nuclearmedicineimagingforbonemetastasesassessmentwhatelsebesidesbonescintigraphyintheeraofpersonalizedmedicine |